Arcutis Reports P-IIb Study Results of Roflumilast for the Treatment of Plaque Psoriasis
Shots:
- The P-IIb study evaluating roflumilast (qd, 0.3% & 0.15%) vs vehicle in a ratio (1:1:1) in 331 patients aged 18-89yrs. chronic PsO
- The results showed a greater improvement in itch @2wk. as assessed by WI-NRS & PSD ≥4-point improvement as early as 2wk. in a subset of patients with a baseline WI-NRS ≥6, improvements in itch-related sleep loss @6 through 12wk. as measured by itch-related sleep loss NRS, an improvement on DLQI Score @6wk. for those treated with roflumilast & for both treated groups @12wk. The results were published in the American Journal of Clinical Dermatology
- Zoryve (roflumilast) cream 0.3% was approved for adults & adolescents with mild to sev. PsO, incl. intertriginous psoriasis in July 2022
Ref: Globenewswire | Image: Arcutis
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
